CAROZANG Trademark

Trademark Overview

On Saturday, August 15, 2020, a trademark application was filed for CAROZANG with the United States Patent and Trademark Office. The USPTO has given the CAROZANG trademark a serial number of 90116464. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, March 22, 2023. This trademark is owned by ONNI Therapeutics LLC. The CAROZANG trademark is filed in the Pharmaceutical Products category with the following description:

Nutraceuticals for use as a dietary supplement; nutraceuticals for use as a dietary supplement for cancer patients
carozang

General Information

Serial Number90116464
Word MarkCAROZANG
Filing DateSaturday, August 15, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, March 22, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 10, 2021

Trademark Statements

Goods and ServicesNutraceuticals for use as a dietary supplement; nutraceuticals for use as a dietary supplement for cancer patients

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 17, 2020
Primary Code005
First Use Anywhere DateTuesday, June 15, 2021
First Use In Commerce DateWednesday, October 12, 2022

Trademark Owner History

Party NameONNI Therapeutics LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressArlington, MA 02474
Party NameONNI Therapeutics LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressArlington, MA 02474

Trademark Events

Event DateEvent Description
Wednesday, March 22, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, March 22, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Wednesday, March 22, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, December 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, December 6, 2022NON-FINAL ACTION E-MAILED
Tuesday, December 6, 2022SU - NON-FINAL ACTION - WRITTEN
Monday, November 14, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, November 14, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, November 14, 2022ASSIGNED TO LIE
Monday, November 7, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 9, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 9, 2022NON-FINAL ACTION E-MAILED
Monday, May 9, 2022SU - NON-FINAL ACTION - WRITTEN
Monday, April 18, 2022STATEMENT OF USE PROCESSING COMPLETE
Friday, April 1, 2022USE AMENDMENT FILED
Monday, April 18, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 1, 2022TEAS STATEMENT OF USE RECEIVED
Tuesday, October 5, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 10, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 10, 2021PUBLISHED FOR OPPOSITION
Wednesday, July 21, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 2, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 1, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 1, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 1, 2021ASSIGNED TO LIE
Tuesday, May 4, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 16, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 16, 2020NON-FINAL ACTION E-MAILED
Wednesday, December 16, 2020NON-FINAL ACTION WRITTEN
Thursday, December 10, 2020ASSIGNED TO EXAMINER
Thursday, September 17, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 19, 2020NEW APPLICATION ENTERED

Related Keywords

carozang nutraceuticals supplement dietary patients cancer